Results 121 to 130 of about 118,257 (252)

Evaluation of Platelet Activation by HIV Protease Inhibitors – The HIV-PLA II Study

open access: yesHIV/AIDS: Research and Palliative Care, 2021
Gerrit Kann,1,* Junaid Owasil,1,* Karina Kuczka,2 Annette Haberl,1 Timo Wolf,1 Pavel Khaykin,1 Sebastian Harder,2 Christoph Stephan,1 Nils von Hentig1 1HIVCENTER, Medical HIV Treatment and Research Unit, Johann Wolfgang Goethe University ...
Kann G   +8 more
doaj  

Immune non‐response despite effective antiretroviral therapy in people living with HIV: A review of potential mechanisms, biomarkers and therapeutic approaches

open access: yesHIV Medicine, EarlyView.
Abstract Introduction A proportion of people living with HIV (PLWH) fail to restore their CD4 count or their CD4/CD8 ratio despite effective antiretroviral therapy (ART). PLWH with immune non‐response (INR) are at a higher risk of both AIDS and non‐AIDS events. The underlying mechanisms of INR remain unclear.
Charlotte Silvestre   +2 more
wiley   +1 more source

HIV Protease Inhibitors and Insulin Sensitivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

open access: yesFront Pharmacol, 2021
Kajogoo VD   +8 more
europepmc   +1 more source

Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization [PDF]

open access: yes, 2015
Current guidelines recommend treatment optimization in virologically suppressed patients through switching/ simplification strategies to minimize long-term toxicities and improve adherence. The assessment of inflammation/ coagulation profiles may support
FALASCA, FRANCESCA   +6 more
core  

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir‐based antiretroviral therapy

open access: yesHIV Medicine, EarlyView.
Abstract Background Darunavir‐based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in these populations despite limited real‐world outcome ...
Rhianna Sheridan   +6 more
wiley   +1 more source

Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease. [PDF]

open access: yesVirol J, 2020
Mahdi M   +5 more
europepmc   +2 more sources

Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system

open access: yesHIV Medicine, EarlyView.
Abstract Objective Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged.
Leidan Zhang   +8 more
wiley   +1 more source

Perinatal and early infant outcomes after first‐versus second‐generation integrase strand transfer inhibitor use in pregnancy

open access: yesHIV Medicine, EarlyView.
Abstract Introduction Integrase strand transfer inhibitors (INSTIs) are first‐line antiretroviral medications used in pregnancy. Pre‐clinical research suggests adverse effects in human stem cells associated with second‐ versus first‐generation INSTIs.
Rosa Balleny   +12 more
wiley   +1 more source

Calibration and discrimination ability of the Dat'AIDS score in people living with HIV aged 70 years and older from the Dat'AIDS cohort

open access: yesHIV Medicine, EarlyView.
Abstract Objective The Dat'AIDS score was developed to predict 5‐year mortality risk in people living with HIV aged 60 and older. However, its validity in people living with HIV aged 70 years and older needed confirmation. Methods This was a multicentre prospective cohort study in the Dat'AIDS French cohort.
Abeo Mousse   +337 more
wiley   +1 more source

Home - About - Disclaimer - Privacy